middle.news
Immutep Wins FDA Orphan Drug Status for Eftilagimod Alfa in Soft Tissue Sarcoma
9:36am on Wednesday 15th of April, 2026 AEST
•
Biotechnology
Read Story
Immutep Wins FDA Orphan Drug Status for Eftilagimod Alfa in Soft Tissue Sarcoma
9:36am on Wednesday 15th of April, 2026 AEST
Key Points
FDA grants Orphan Drug Designation for eftilagimod alfa in rare soft tissue sarcoma
Phase II EFTISARC-NEO trial shows significant tumour response with efti combo therapy
Designation offers regulatory benefits including seven years market exclusivity
Immutep reassessing clinical strategy after halting Phase III TACTI-004 trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE